

ImmuPharma PLC
("ImmuPharma" or the "Company")

Total Share Capital Notification

The following replaces the 'Total Share Capital Notification' announcement released on 30 September 2020 at 7.01am (BST) under RNS No 5041A.

In Section 2 below the reference to "Share Options in whole or part" should have stated 25,640,254 not 15,703,942.

The full amended text is shown below.

ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company announces that in accordance with its obligations to the Company's Euronext listing and following an application of Article 15 of the Belgian Law of 2 May 2007, the total number of shares with voting rights and the total number of voting rights are set out below:

Situation as at 16 June 2020

1. Information to be provided for on the basis of Article 15, §1, al. 1

Total of share capital (nominal value)	:	£ 24,628,580
Total number of shares with existing voting rights (= denominator) – one vote per share	:	246,285,805

2. Additional information to be provided on the basis of Article 15, §1, al. 2

In respect to the announcement on 11 June 2020: "Investment from two specialist US healthcare investors"

Convertible Securities (in whole or in part) into ordinary shares currently outstanding. The total conversion would result in an equal number of voting rights	:	10,734,166
Share options (in whole or in part) The exercise of the options would result in the creation of an equal number of ordinary shares and voting rights.	:	25,640,254

In respect to the announcements on 30 March 2020: "Subscription to raise £1.5m" and 2 September 2020 "Placing to raise £6.5m"

Warrants over ordinary shares (in whole or in part) The exercise of the warrants would result in the creation of an equal number of ordinary shares and voting rights	:	3,343,045
--	---	-----------

Other outstanding rights to subscribe ordinary shares as detailed in the Annual Report 2019 (Report and consolidated financial Statements for the year ended 31 December 2019)

Share options (in whole or in part) : 16,368,850
The exercise of the options would result in the creation of an equal number of ordinary shares and voting rights

This situation (the denominator) serves as a basis for the notification of major holdings by shareholders.

For further information please contact:

ImmuPharma PLC (www.immupharma.com)	+ 44 (0) 207 152 4080
Tim McCarthy, Chairman	
Dimitri Dimitriou, Chief Executive Officer	
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)	+44 (0) 203 368 3550
Neil Baldwin	
Stanford Capital Partners (Joint Broker)	+44 (0) 203 815 8880
Patrick Claridge, John Howes	
SI Capital (Joint Broker)	+44 (0) 1483 413500
Nick Emerson	
4Reliance (Euronext Growth Listing Sponsor)	+32 (0) 2 747 02 60
Jean-Charles Snoy	
Degroof Petercam (Liquidity Provider)	+32 (0) 2 287 95 34
Erik De Clippel	
Backstage Communication	
Olivier Duquaine	+32 (0) 477 504 784
Gunther De Backer	+32 (0) 475 903 909

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase III trial for Lupuzor™ and commercialise in the US.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

